Haemonetics Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 2/6
Haemonetics hat ein Gesamteigenkapital von $960.0M und eine Gesamtverschuldung von $807.8M, wodurch sich der Verschuldungsgrad auf 84.1% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen $2.2B bzw. $1.2B. Haemonetics Das EBIT des Unternehmens beträgt $206.8M, so dass der Zinsdeckungsgrad 10.6 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von $180.5M.
Wichtige Informationen
135.1%
Verhältnis von Schulden zu Eigenkapital
US$1.22b
Verschuldung
Zinsdeckungsgrad | 11.2x |
Bargeld | US$346.07m |
Eigenkapital | US$905.37m |
Gesamtverbindlichkeiten | US$1.64b |
Gesamtvermögen | US$2.54b |
Jüngste Berichte zur Finanzlage
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
Sep 09Is Haemonetics (NYSE:HAE) A Risky Investment?
Oct 24Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Jul 07Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Apr 06We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease
Jan 05Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly
Oct 04Recent updates
These 4 Measures Indicate That Haemonetics (NYSE:HAE) Is Using Debt Reasonably Well
Sep 09What You Can Learn From Haemonetics Corporation's (NYSE:HAE) P/E
Aug 14Are Investors Undervaluing Haemonetics Corporation (NYSE:HAE) By 46%?
Jul 18Haemonetics Undervalued As It Passes Into A Period Of Softer Reported Growth
Jun 21Does Haemonetics (NYSE:HAE) Deserve A Spot On Your Watchlist?
Apr 30Haemonetics Corporation's (NYSE:HAE) Share Price Matching Investor Opinion
Apr 12Haemonetics Corporation (NYSE:HAE) Shares Could Be 35% Below Their Intrinsic Value Estimate
Mar 07Haemonetics Corporation: Improved Performance, Another Bolt-On Deal
Mar 06The Strong Earnings Posted By Haemonetics (NYSE:HAE) Are A Good Indication Of The Strength Of The Business
Feb 15The Price Is Right For Haemonetics Corporation (NYSE:HAE)
Jan 01Haemonetics: Solid Performance Of This Blood Play
Nov 22Here's Why We Think Haemonetics (NYSE:HAE) Might Deserve Your Attention Today
Nov 14Is Haemonetics (NYSE:HAE) A Risky Investment?
Oct 24Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment
Oct 13Haemonetics' Fiscal Q1 2024: Blood, Sweat, And Stellar Gains
Aug 09Here's Why Haemonetics (NYSE:HAE) Has Caught The Eye Of Investors
Aug 09An Intrinsic Calculation For Haemonetics Corporation (NYSE:HAE) Suggests It's 48% Undervalued
Jul 25Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Jul 07Haemonetics (NYSE:HAE) Has A Rock Solid Balance Sheet
Apr 06Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 46% Undervaluation?
Mar 19Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer
Feb 16Haemonetics: Earnings Rate Of Change Justifies High Multiples
Feb 01We Think Haemonetics (NYSE:HAE) Can Manage Its Debt With Ease
Jan 05Is There An Opportunity With Haemonetics Corporation's (NYSE:HAE) 36% Undervaluation?
Dec 15Haemonetics Q2 2023 Earnings Preview
Nov 04Haemonetics (NYSE:HAE) Seems To Use Debt Rather Sparingly
Oct 04Haemonetics: Plasma Thesis Continues To Play Out, Reiterate Buy
Sep 06Haemonetics reaches new 52-week high; shares up 41% YTD
Aug 24Haemonetics reports Q2 earnings beat; raises FY22 guidance
Aug 10A Look At The Intrinsic Value Of Haemonetics Corporation (NYSE:HAE)
Aug 10Here's Why Haemonetics (NYSE:HAE) Can Manage Its Debt Responsibly
Jul 03Haemonetics: Upside Case Hinges On Blood Plasma Collection Market
Jun 11Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: HAEDie kurzfristigen Aktiva des Unternehmens ($768.9M) übersteigen seine kurzfristigen Passiva ($300.4M).
Langfristige Verbindlichkeiten: HAEDie kurzfristigen Vermögenswerte des Unternehmens ($768.9M) decken seine langfristigen Verbindlichkeiten ($935.2M) nicht.
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: HAEDie Nettoverschuldung im Verhältnis zum Eigenkapital (65.3%) wird als hoch angesehen.
Schulden abbauen: HAEDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 53.2% auf 84.1% gestiegen.
Schuldendeckung: HAEDie Schulden des Unternehmens sind nicht ausreichend durch den operativen Cashflow (11.1%) gedeckt.
Zinsdeckung: HAEDie Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (10.6x Coverage) gut gedeckt.